[
  {
    "ts": "2025-08-12T07:29:18+00:00",
    "headline": "GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/gild-q2-deep-dive-hiv-072918920.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "07fc94a2-d0ce-32d4-88c5-a69191748e1a",
      "content": {
        "id": "07fc94a2-d0ce-32d4-88c5-a69191748e1a",
        "contentType": "STORY",
        "title": "GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus",
        "description": "",
        "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.",
        "pubDate": "2025-08-12T07:29:18Z",
        "displayTime": "2025-08-12T07:29:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gild-q2-deep-dive-hiv-072918920.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gild-q2-deep-dive-hiv-072918920.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-12T00:19:45+00:00",
    "headline": "Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines Agency’s CHMP for lenacapavir (Yeytuo®), a twice-yearly injectable HIV PrEP alternative. It will be the first of its kind in the EU if it is […]",
    "url": "https://finance.yahoo.com/news/gilead-receives-favorable-chmp-opinion-001945031.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f63985c5-e7ce-3af4-ab9a-af476eb5e88e",
      "content": {
        "id": "f63985c5-e7ce-3af4-ab9a-af476eb5e88e",
        "contentType": "STORY",
        "title": "Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines Agency’s CHMP for lenacapavir (Yeytuo®), a twice-yearly injectable HIV PrEP alternative. It will be the first of its kind in the EU if it is […]",
        "pubDate": "2025-08-12T00:19:45Z",
        "displayTime": "2025-08-12T00:19:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8a4d0f18e19b1a295c4a0dd2c49c70c8",
          "originalWidth": 838,
          "originalHeight": 571,
          "caption": "Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/plkhttYLeJ_1OxgFOXUvPA--~B/aD01NzE7dz04Mzg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8a4d0f18e19b1a295c4a0dd2c49c70c8.cf.webp",
              "width": 838,
              "height": 571,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B4rQA.VTwAtp091pk1xtgw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8a4d0f18e19b1a295c4a0dd2c49c70c8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-receives-favorable-chmp-opinion-001945031.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-receives-favorable-chmp-opinion-001945031.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]